Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure
Pfizer Inc. sees a path forward for an experimental lung cancer drug in combination with other medicines, despite it failing a key clinical trial.
By Ashleigh Furlong ยท Bloomberg
Pfizer Inc. sees a path forward for an experimental lung cancer drug in combination with other medicines, despite it failing a key clinical trial.